of novel formulations
There is much research focused on developing new strategies to increase the vitreous residence times of macromolecular drugs to decrease the frequency of intravitreal injections.
The PK-Eye™ is for the evaluation and optimisation of novel ocular formulations and delivery systems for the vitreous. The PK-Eye™ can accelerate the development of longer-lasting therapeutic dosage forms during preclinical development that are needed to treat chronic blinding conditions.
Optimisation of a bevacizumab and a protein conjugate (PEG10-Fabrani) hydrogel formulation using the PK-Eye™
Awwad et al, Macromol Biosci. 2018; 18 (2):1700255